RheumaGen has filed a notice of an exempt offering of securities to raise $15 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, RheumaGen is raising up to $15,000,000.00 in new funding. Sources indicate that as part of senior management Chief Legal Officer, Ryan Hart played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About RheumaGen
RheumaGen is developing a breakthrough gene editing treatment that has the potential to cure Rheumatoid Arthritis. Our mission is to cure autoimmune diseases, not just temper their symptoms. Founded in 2019, RheumaGen is a preclinical cell and gene therapy company developing cures for autoimmune diseases by attacking them at their source: the Human Leukocyte Antigen (HLA) gene. We tackle big problems. We look for science-based, patient-friendly solutions.
To learn more about RheumaGen, visit http://www.rheumagen.com/
Contact:
Ryan Hart, Chief Legal Officer
720-569-0180
https://www.linkedin.com/in/ryan-h-20b8444/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.